|Bid||113.32 x 800|
|Ask||113.72 x 1300|
|Day's Range||112.40 - 114.32|
|52 Week Range||85.00 - 125.48|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||138.26|
For the past year, the share price of Gilead Sciences (NASDAQ:GILD) has been a flat-line. GILD stock is also down about 18% since its high set in July.Source: Shutterstock But on Thursday, the company will report its first quarter results. So might there be something to perk up Gilead stock?Well, if anything, the general pessimism may be setting things up for some much-needed gains. GILD stock really does look like an interesting value play.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOK, then, as for Wall Street consensus, it is calling for revenues to rise about 4% to $5.3 billion and earnings to come in at $1.61 per share.A big problem that's dogged Gilead stock is the competition for its treatments in the lucrative HIV and hepatitis C categories. Like many other big pharma companies, GILD has been struggling to find ways to bolster its pipeline. * 7 Dividend Stocks That Could Double Over the Next Five Years Now the company has been making a strong push in the market for CAR-T treatments, which is where a patient's own T-cells are used to fight cancer. To this end, Gilead purchased one of the leaders in the industry, Kite Pharma, in 2017. Yet the performance has been disappointing, as revenues have fallen below expectations. In the latest earnings report, Gilead took an $820 million impairment charge for the deal. Costly and Complex TreatmentsThis is not to imply that the growth potential is not significant. But it could take time to get to critical mass because of the costs and complexities of the treatments.In the quarter, Gilead also had some other notable highlights like: * The company entered a strategic collaboration with insitro, which is a startup that leverages AI (artificial intelligence) and machine learning to research new therapies. The agreement is focused on patients with nonalcoholic steatohepatitis (NASH), which is a progressive liver disease. Keep in mind that Gilead probably needs to look at unconventional approaches. After all, the company's treatments for NASH have had mixed results, as seen with the recent failure of Selonsertib (in a Phase 3 trial, the placebo actually had better results). * On a more optimistic note, Gilead got good news with its Phase 3 trials for Filgotinib, which is for rheumatoid arthritis. The company is developing the drug in partnership with Galapagos (NASDAQ:GLPG). While there are other treatments on the market, such as from Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE), Filgotinib does appear to have fewer side effects. * Gilead's Executive Vice President of Oncology Therapeutics, Dr. Alessandro Riva, announced that he would leave the company. A search is underway for his replacement. Bottom Line On Gilead StockThe HIV and hepatitis C franchises are high-margin businesses that produce enormous cash flows. For example, last year Gilead reported operating cash flow of $8.4 billion. In all, there is $31.5 billion in the bank. * 7 Cloud Stocks to Buy Now What's more, Gilead is fairly shareholder friendly. In 2018, the company bought back $2.9 billion of its shares. There is also an attractive dividend yield of 3.88%.Oh, and the valuation in the Gilead stock price today is quite reasonable, with the forward-price to earnings ratio of about 9.4x. All in all, it seems like much of the bad news is already baked in.So then what about the pipeline? Isn't this a problem? Again, the Car-T business is far from easy but this is to be expected with any cutting-edge innovation. But of course, there is much more than this for Gilead. Consider that the company has been finding more indications for existing drugs, such as with its HIV treatments.But looking ahead, and this week's Gilead earnings date, it seems like a good bet that the company will need to continue to focus on aggressive M&A. And Gilead Sciences certainly has the war chest for this.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 7 U.S. Shale Oil Stocks to Buy as Prices Rise * 10 Stocks to Sell Before They Give Back 2019 Gains * 10 Oversold Stocks to Run From Compare Brokers The post Will Gilead Stock Get A Needed Boost From This Week's Earnings Report? appeared first on InvestorPlace.
Key Q1 2019 results: Group revenues of €40.9 million Operating loss €53.2 million Net loss of €48.7 million End of first quarter cash and cash equivalents €1.2 billion.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX;.
On 10 April 2019, the board of directors of Galapagos approved "Warrant Plan 2019 RMV," intended for the employees of its French subsidiary, Galapagos SASU, and "Warrant Plan 2019", intended mainly for the employees of the company and its subsidiaries, and for directors and an independent consultant of the company, within the framework of the authorized capital. Under these warrant plans, 2,070,000 warrants were created, subject to acceptances, and offered to the beneficiaries of the plans.
Analysts at UBS upgraded shares of Gilead Sciences Inc. to buy from neutral and boosted the price target on the stock to $77 from $75 on Wednesday, citing "two important clinical wins" that could each one day bring in more than $2 billion in revenue. "Following the failure of selonsertib in NASH, Gilead has rattled off two important clinical wins: positive Descovy PrEP data and filgotinib FINCH1/3 data," UBS analyst Carter Gould wrote in a note to clients. Descovy is currently approved to treat HIV, but it is not approved to be used as pre-exposure prophylaxis, or PrEP, to reduce the risk of acquiring the virus. Filgotinib is a promising investigational rheumatoid arthritis drug that Gilead is developing with Galapagos NV . "On the back of Biktarvy growth, Descovy PrEP utilization, and filgotinib, we have increased conviction that the top-line will grow and model faster growth," Gould wrote, adding he saw "less downside risk relative to peers (Amgen and Biogen)." He also raised his full-year EPS estimate for Gilead to $6.85 from $6.73, citing strong sales trends for HIV drugs Biktarvy and Truvada and lower projected SG&A expense due to the failure of selonsertib, an investigational drug designed to treat nonalcoholic steatohepatitis (NASH) that recently failed to meet the primary endpoint in a Phase 3 study. Shares of Gilead have gained 7.4% in the year to date, while the S&P 500 has gained 15%.
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Nomination of Mr. Peter Guenter for Galapagos' board of directors Mechelen, Belgium; 29 March 2019, 22.15 CET; regulated information - Galapagos NV (Euronext & NASDAQ:.
Shares of Belgium-based biotech Galapagos NV soared 23% on Friday after the company, together with pharmaceutical giant Gilead Sciences Inc., announced Thursday evening that two Phase 3 trials of their investigational rheumatoid arthritis drug had achieved their primary endpoints.
rose sharply Friday after the biotechnology company announced positive results for both doses of its rheumatoid arthritis drug, filgotinib, in Phase 3 trials. , showed patients improving more than a placebo in attaining an American College of Rheumatology 20% response, according to a company press release. The ACR20 is the baseline measure to evaluate rheumatoid arthritis treatments in clinical trials so that patients express a 20% improvement in at least three of five criteria determined by the ACR, according to the organization.
The two bioetchs said Phase 3 trial data for rheumatoid arthritis treatment filgotinib showed the drug met its primary endpoints and exhibited a safety profile consistent with previous research.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 28) Baxter International Inc (NYSE: BAX ) Constellation ...
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City,.
-- Filgotinib 100 mg and 200 mg Plus Methotrexate Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone --
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response --
-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile.
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile --
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior.
NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...
Mechelen, Belgium; 20 March 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant.